Replies to post #113797 on Vivos Inc (RDGL)

[Arch_Investor]

What are you talking about LOL!!!...
It's already been done the exact same way go look up Therasphere.
Same technology different delivery system....and guess what!? dogs to humans....
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514171/

https://www.theraspheretrials.com/Home

The difference? Theresphere is glass Microns. RodioGel is not glass. Y90 has already been approved on many formats.
Do some more DD

[champana]

Really? Canine data isn't enough?

5 cases where it was:
https://www.accessdata.fda.gov/cdrh_docs/reviews/k060159.pdf

https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm348890.pdf

https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN130004.pdf

https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM427866.pdf

https://www.accessdata.fda.gov/cdrh_docs/reviews/K130651.pdf

[Cancer Fighter]

Inaccurate and nonsensical grievous. DeNovo for humans is extremely likely at some point in the not to distant future. RDGL'S Yttruim -90 based brachytherapy device is groundbreaking. This device has not been submitted by Battelle before to the FDA by the way.

Further, Isopet will generate a lot of money for shareholders as times goes on. The future is explosively bright for shareholders and a death sentence for short sellers.

Finally, Trump signed the Right to Try act a while back -- this may be an avenue RDGL can use to get their foot in the door for human trials even quicker than we all realize. RDGL has expressed an interest in pursuing Right to Try for that young woman with brain cancer.

Plus RadioGel has been classified as a device which also can speed the process up by the FDA.

By the way, Treating animals alone will make shareholders wealthy.